Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Cough, Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 67
States / cities: Jasper, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 59 more

Conditions: AADC Deficiency
Interventions: AAV2-hAADC; Drug
Lead sponsor: Krzysztof Bankiewicz; Other
Eligibility: 24 Months and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 3
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Alzheimer Disease
Interventions: Low Dose Benfotiamine, High Dose Benfotiamine, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 89 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 35 more

Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
Interventions: twiist insulin delivery system; Device
Lead sponsor: Deka Research and Development; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: La Jolla, California • Newport Beach, California • Santa Barbara, California + 24 more

Conditions: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions: cabozantinib, atezolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more

Conditions: Cervical Cancer
Interventions: gemcitabine hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Epilepsy
Interventions: Activa™ PC and Percept™ PC Neurostimulation Systems; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Non-interventional study.; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 47
States / cities: Highlands Ranch, Colorado • Wheat Ridge, Colorado • Clearwater, Florida + 43 more

Conditions: Anemia Associated With Chronic Kidney Disease (CKD)
Interventions: Vadadustat, Mircera®; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 58
States / cities: Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more

Conditions: Congenital Heart Disease, Congenital Heart Disease (CHD)
Interventions: Ductus Arteriosus Stent; Device
Lead sponsor: Starlight Cardiovascular Inc; Industry
Eligibility: 1 Minute to 6 Months
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 8 more

Conditions: Breast Cancer
Interventions: marimastat; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 25
States / cities: Scottsdale, Arizona • Chicago, Illinois • Urbana, Illinois + 22 more

Conditions: Congenital Heart Disease, Health Behavior
Interventions: Heart2Heart; Behavioral
Lead sponsor: Kristen Fox; Other
Eligibility: 12 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Spinal Cord Injuries, Healthy
Interventions: Downhill Eccentric Treadmill Training with Electrical Stimulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Stroke
Interventions: IV rt-PA alone, endovascular therapy; Drug · Other
Lead sponsor: Joseph Broderick; Other
Eligibility: 18 Years to 82 Years
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: HRAS Gene Mutation, HNSCC
Interventions: Tipifarnib, HRAS Detection Assay; Drug · Device
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 29
States / cities: Los Angeles, California • San Francisco, California • Whittier, California + 23 more

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, Glimepiride, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Triptorelin Pamoate; Other · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 39 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 201
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Cystic Fibrosis (CF)
Interventions: Common form supplementation, Uncommon nutrient supplementation; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy; Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more

Conditions: Pancreatic Cancer
Interventions: TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine; Combination Product
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Bakersfield, California + 25 more

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: CB-183,315, Placebo, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more

Conditions: Acute Lung Injury
Interventions: Calfactant, Air placebo; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Months to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 12 more

Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions: Dersimelagon, Placebo; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 13
States / cities: Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more

Search by objective public record fields.

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Innovative Automated Insulin Delivery System for Type 2 Diabetes

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

Heart2Heart for Teens With CHD

Eccentric Muscle Training, Stimulation, and Biomarkers in SCI

Interventional Management of Stroke (IMS) III Trial

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Nutrition Supplement for Cystic Fibrosis

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Study of CB-183,315 in Participants With Clostridium Difficile Infection

CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP